Skip to main content
OpenTrials
Completed

NCT Number: NCT01251042

Comparison Between Return and Wastage of Your Own Blood, Collected During Spinal Surgery, for Verification of Safety When Returning Blood

The study is an open, randomized, controlled, single-centre study including a total of 42 evaluable subjects scheduled for spinal surgery with an approximate expected bleeding of 800-1500 ml. The Sangvia® Blood Salvage System will be set up for all subjects to collect blood intra-operatively. When the transfusion bag is filled, i.e. when around 500 ml of blood has been collected, the subject will be randomized to either be retransfused with the blood collected (investigational group) or not (control group). The primary objective for this study is to investigate the blood quality and isolate the systemic effects in intra-operatively collected blood. The systemic p-Hb concentration has been chosen as the primary outcome variable based on previous experience and literature and is considered as the major safety concern for the study subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinical Trial Unit, Glostrup Hospital, University of Copenhagen

Glostrup Municipality, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of informed consent.
  • Male and female subjects aged 18 years and over subjected to spinal surgery with an approximate expected bleeding of 800-1500 ml.
  • Subjects classified as ASA Physical Status Classification System class P1, P2 or P3 according to the American Society of Anaesthesiology.

Exclusion criteria

  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site).
  • Previous enrolment or randomisation of treatment in the present study.
  • Participation in another clinical study, that may interfere with the present study.
  • Severe non-compliance to protocol as judged by the investigator and/or Astra Tech.
  • Haemophilia.
  • Hyperkalemia (i.e. values above the normal reference values at study site).
  • Symptoms of impaired renal function including creatinine clearance levels (using the Cockcroft-Gault formula) <30 ml/min.
  • Malignancy in the area of the operative site.
  • Current or expected use of cytotoxic drugs.
  • Symptoms of systemic infection or local infection in the operation field.
  • Pregnancy.
  • Sickle cell anaemia and/or pre-operative Hb concentration <11 g/dl (6,8 mmol/l).
  • Use of recombinant erythropoietin (EPO) or fibrin sealant.
  • Use of other autologous blood transfusion than with the Sangvia® system (e.g. CellSaver and pre-donation) or other blood saving techniques (e.g. normovolemic hemodilution).
  • Hypotensive anesthesia.
  • Use of antithrombotic medication within 5 days of surgery (NSAID, Clopidogrel).

Treatment and study plan

Sangvia

Device

The Sangvia® Blood Salvage System used to collect blood intra-operatively.

Primary outcomes

  1. Difference in Plasma Free Hemoglobin (p-Hb) Concentration

    Time frame: At screening and 24 hours after surgery (surgery takes place 1-7 days after screening)

    Difference in plasma free hemoglobin (p-Hb) concentration between screening and 24 hours after surgery

Secondary outcomes

  1. Plasma Free Hemoglobin (p-Hb) Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic plasma free hemoglobin (p-Hb) concentration from screening until 96 hours after surgery.

  2. Hemoglobin Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic hemoglobin concentration from screening until 96 hours after surgery.

  3. Potassium Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic potassium concentration from screening until 96 hours after surgery.

  4. Creatinine Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic creatinine concentration from screening until 96 hours after surgery.

  5. Interleukin-1-alpha (IL-1-α) Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic IL-1-α concentration from screening until 96 hours after surgery.

  6. Interleukin-6 (IL-6) Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic IL-6 concentration from screening until 96 hours after surgery.

  7. Interleukin-8 (IL-8) Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic IL-8 concentration from screening until 96 hours after surgery.

  8. Interleukin-10 (IL-10) Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic IL-10 concentration from screening until 96 hours after surgery.

  9. Tumor Necrosis Factor Alpha (TNF-α) Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic TNF-α concentration from screening until 96 hours after surgery.

  10. Interferon Gamma (IFN-γ) Concentration

    Time frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)

    Systemic IFN-γ concentration from screening until 96 hours after surgery.

  11. Mean Blood Loss Volume

    Time frame: After surgery (surgery takes place 1-7 days after screening)

    Estimated blood loss during and after surgery.

  12. Frequency of Allogenic Blood Transfusion

    Time frame: Up until 96 hours after surgery (surgery takes place 1-7 days after screening)

Sponsors and collaborators

Lead sponsor

Wellspect HealthCare

Industry

Registry information

Official study title

A Prospective, Randomized, Controlled Study on Intra-operative Autologous Transfusion With the Sangvia® Blood Salvage System in Spinal Surgery

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Dec 1, 2010
Registry last updated
Nov 11, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.